Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04756401 · OUTCOME

Overall Survival (OS)

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma · Source last updated 2026-09-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
2 years

What was measured

The overall survival (OS) is defined as the time from registration to death due to any cause. The distribution of OS will be estimated using method of Kaplan-Meier.

Groups in this outcome

Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)

Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\> \> Carfilzomib: Given IV\> \> Daratumumab: Given IV\> \> Dexamethasone: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> Selinexor: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)8

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)NANot reportedNANAMedian OS and CI are not able to be estimated due to a low number of deaths
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Median OS and CI are not able to be estimated due to a low number of deaths
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
The overall survival (OS) is defined as the time from registration to death due to any cause. The distribution of OS will be estimated using method of Kaplan-Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\> \> Carfilzomib: Given IV\> \> Daratumumab: Given IV\> \> Dexamethasone: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> Selinexor: Given PO
    id
    OG000
    title
    Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)
param Type
MEDIAN
reporting Status
POSTED
time Frame
2 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice